BIIB vs RAPP
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. RAPP: Rapport Therapeutics is a clinical-stage biotechnology company developing precision medicines for neurological disorders using its proprietary RAP platform to target specific neural circuits.
Side-by-side fundamentals
| Metric | BIIB | RAPP | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $218.12 | $48.24 | |
| Market cap as of 2026-08-24 | $32.2B | $2.3B | |
| P/E as of 2026-08-24 | 38.63 | n/a | |
| PEG as of 2026-08-24 | 10.99 | -0.67 | RAPP lower |
| Net margin as of 2026-08-24 | +8.3% | n/a | |
| Gross margin as of 2026-08-24 | +74.0% | n/a | |
| Operating margin as of 2026-08-24 | +10.9% | n/a | |
| ROE as of 2026-08-24 | +4.5% | -29.0% | BIIB higher |
| ROA as of 2026-08-24 | +2.8% | -27.4% | BIIB higher |
| Debt / equity as of 2026-08-24 | 0.43 | 0.00 | RAPP lower |
| Revenue growth (YoY) as of 2026-08-24 | +0.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.9% | n/a | |
| Beta as of 2026-08-24 | 0.49 | 2.47 | |
| 1-year return as of 2026-08-24 close | +56.6% | +223.1% | RAPP higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.